Obesity trials recruiting in North Carolina

All Obesity trials nationally

Cities in North Carolina

Recruiting trials in North Carolina

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Morehead City, Winston-Salem
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Greensboro, Monroe, Morehead City, New Bern
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Greensboro, Raleigh, Rocky Mount, Statesville
• A Mobile Intervention to Reduce Pain and Improve Health-III
  NCT06623669 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
  NCT07570758 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · North Carolina: Monroe
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Chapel Hill, Durham, Morehead City
• A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
  NCT07639021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Wilmington
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Morehead City, Winston-Salem
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Wilmington
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Greensboro, Greenville, Morehead City, Statesville
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Apex, Concord, Durham, Greenville
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · North Carolina: Charlotte, Durham, Fayetteville, Morehead City
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Greensboro, Morehead City, Wilmington
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Monroe
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill, Greensboro, Morehead City, Wilmington
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Morehead City, Shelby
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Durham, Greenville, Morehead City
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Greenville, Morehead City, Raleigh
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
  NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · North Carolina: Morehead City
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
  NCT07153471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Shelby
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Monroe, Statesville, Wilmington
• A Study of Pitolisant in Patients With Prader-Willi Syndrome
  NCT06366464 · Phase: Phase 3 · Ages: 6 Years and older · Sex: All (male and female) · North Carolina: Morrisville
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Statesville
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Salisbury
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Greensboro, Monroe, Morehead City, New Bern
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Cary, Huntersville
• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
  NCT07595549 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Greensboro, Wilmington
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
  NCT07477704 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · North Carolina: Durham, Wilmington
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · North Carolina: Morehead City, Wilmington
• AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
  NCT07503210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Greensboro, Wilmington
• AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
  NCT07339423 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill, Greensboro, Wilmington
• AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07509307 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Statesville
• Ablation Registry (Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty for Weight Loss)
  NCT06420700 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · North Carolina: Cary
• Breastfeeding Intervention to Prevent Obesity Among Children
  NCT06921382 · Phase: Not applicable (e.g. observational or device study) · Ages: 5 Days and older · Sex: All (male and female) · North Carolina: Greensboro
• Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
  NCT05082519 · Phase: Phase 2 · Ages: 7 Years to 25 Years · Sex: All (male and female) · North Carolina: Charlotte
• Comparing the Effects of Front-of-Package Labeling Schemes in Indonesia
  NCT07526584 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.
  NCT06991296 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 60 Years · Sex: All (male and female) · North Carolina: Kannapolis
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · North Carolina: Charlotte, Durham, Fayetteville, New Bern
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
  NCT07284979 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Morehead City, Morrisville
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Greensboro, Monroe, Morehead City, Morrisville
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Morehead City
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Morehead City, Raleigh, Wilmington
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · North Carolina: Charlotte, Durham, Greensboro, Monroe
• Evaluation of Child Care Staff Weight Management Program
  NCT05656807 · Phase: Not applicable (e.g. observational or device study) · Ages: 2 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
  NCT07607587 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Monroe, Wilmington
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Hickory, Shelby
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
  NCT07684144 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Morehead City
• FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
  NCT06724406 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• Fundus Ablation Registry (Gastric Fundus Mucosal Ablation for Weight Loss)
  NCT06428617 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · North Carolina: Cary
• Healthy Living Anson Study
  NCT07126587 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• HomeGrown: A Family-based Lifestyle Intervention to Support Healthy Development of Young Children With Down Syndrome
  NCT07296861 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · North Carolina: Chapel Hill
• Inspiratory Pulmonary Rehabilitation for Children With Obesity and Asthma
  NCT05608668 · Phase: Not applicable (e.g. observational or device study) · Ages: 8 Years to 17 Years · Sex: All (male and female) · North Carolina: Durham
• Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure
  NCT07216820 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism
  NCT04328337 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 45 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• Investigating the Impact of Obesity on Pubertal Development in Girls
  NCT02583646 · Phase: Not specified · Ages: 8 Years to 14 Years · Sex: Female · North Carolina: Research Triangle Park
• MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
  NCT06734312 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years to 65 Years · Sex: All (male and female) · North Carolina: Cary
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
  NCT07226765 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Monroe
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
  NCT07225686 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Monroe
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Asheville, Durham, Lenoir, Statesville
• Mechanistic Study of Inspiratory Training in Childhood Asthma (MICA)
  NCT05945355 · Phase: Not applicable (e.g. observational or device study) · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Durham
• Metabolic Inflexibility is Related to Elevated Muscle Anaerobic Glycolysis
  NCT04320264 · Phase: Not specified · Ages: 18 Years to 50 Years · Sex: All (male and female) · North Carolina: Greenville
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · North Carolina: Fayetteville
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · North Carolina: Fayetteville
• NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
  NCT05674799 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 39 Years · Sex: Female · North Carolina: Winston-Salem
• Nutrition and Obesity in Under-Represented Populations: Food Insecurity Research to Advance Science and Improve Health
  NCT06116422 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Months to 24 Months · Sex: All (male and female) · North Carolina: Durham
• ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
  NCT05542407 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · North Carolina: Chapel Hill
• Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults
  NCT06044571 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years to 85 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
  NCT04752293 · Phase: Not specified · Ages: 7 Years to 18 Years · Sex: All (male and female) · North Carolina: Winston-Salem
• Physical Activity and Community EmPOWERment Project
  NCT06740162 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Predicting Appendicular Lean and Fat Mass With Bioelectrical Impedance Analysis Among Adult Patients With Obesity.
  NCT06545435 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Pregnancy Exercise Mode Effect on Childhood Obesity
  NCT04805502 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 45 Years · Sex: Female · North Carolina: Greenville
• Preventing Type 2 Diabetes in Black Emergent Adult
  NCT06848244 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 25 Years · Sex: Female · North Carolina: Chapel Hill
• Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
  NCT07446998 · Phase: Phase 2 · Ages: 65 Years to 100 Years · Sex: All (male and female) · North Carolina: Fayetteville
• REvision of VSG with Ablation of the Mucosa Procedure
  NCT06671119 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 60 Years · Sex: All (male and female) · North Carolina: Cary
• Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
  NCT07752979 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Greensboro, Monroe, Morehead City, New Bern
• Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
  NCT03885245 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · North Carolina: Durham
• The Osteoarthritis Prevention Study
  NCT05946044 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years and older · Sex: Female · North Carolina: Chapel Hill, Winston-Salem
• Tirzepatide in Obesity-Driven Endometrial Cancer
  NCT07065552 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Female · North Carolina: Chapel Hill
• Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer Survivors
  NCT06848491 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 39 Years · Sex: All (male and female) · North Carolina: Chapel Hill